Sarah James

Q: What is Sarah James's success rate?

Sarah James currently has a success rate of 96.86170004762299.

Q: What is the average return of Sarah James's calls?

Their stock ratings have generated an average return of 11.637684217241505.

Cantor Fitzgerald | Healthcare

Sarah James is an analyst from Cantor Fitzgerald specializing in the Healthcare sector. Ranked #1352 out of 4635 analysts, they have issued 36 stock ratings with a success rate of 96.86% and an average return of 11.64%.

Sarah James has a well-established track record, with 36 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 96.86% and an average return of 11.64%, underscoring their expertise and ability to identify winning opportunities for investors.

#1352

Out of 4635

Total Ratings

+96.86%

Success Rate

+11.64%

Average Return

Recent Ratings Analysis

UHS

Hold

Apr 29, 2026

Target

$194.00

Current

$162.54

Performance

—

Sarah James rated UHS as Neutral on Apr 29, 2026, setting a price target of 194. The Hold stance appears justified, as shares hovered around 162.54 with a % move.

CNC

Buy

Apr 29, 2026

Target

$60.00

Current

$49.57

Performance

—

On Apr 29, 2026, CNC was given a Overweight rating by Sarah James, with a target price of 60. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

TBRG

Hold

Apr 24, 2026

Target

$26.25

Current

$25.73

Performance

—

TBRG received a Neutral rating from Sarah James on Apr 24, 2026, aiming for 26.25. Shares remained flat at 25.73, aligning with the neutral rating.

NYXH

Buy

Mar 23, 2026

Target

$11.00

Current

$3.01

Performance

-4.75%

On Mar 23, 2026, Sarah James published a Overweight outlook on NYXH, with a target of 11. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 3.01.

DCGO

Buy

Mar 17, 2026

Target

$3.00

Current

$0.72

Performance

-7.51%

Sarah James on Mar 17, 2026 assigned DCGO a Overweight rating, with a price target of 3. The call has struggled to gain traction, with shares losing 7.51%.

HCAT

Hold

Mar 13, 2026

Target

$4.00

Current

$1.34

Performance

1.52%

On Mar 13, 2026, Sarah James reaffirmed HCAT with a Neutral rating, targeting 4. The neutral call matched muted market action of 1.52%.

MDXG

Buy

Feb 17, 2026

Target

$12.00

Current

$3.40

Performance

-34.11%

MDXG was rated Overweight by Sarah James on Feb 17, 2026, with a price objective of 12. This case shows how bullish projections can fail, with the stock now below 3.4.

HUM

Hold

Feb 12, 2026

Target

$290.00

Current

$229.72

Performance

28.46%

On Feb 12, 2026, Sarah James initiated coverage on HUM with a Neutral rating and target of 290. The Hold stance underestimated the stock’s strength as it gained 28.46%.

MOH

Hold

Feb 09, 2026

Target

$144.00

Current

$185.46

Performance

45.42%

Sarah James issued a Neutral recommendation for MOH on Feb 09, 2026, price target set at 144. A neutral call gave way to stronger-than-expected performance, closing in on 144.

HCA

Buy

Jan 28, 2026

Target

$588.00

Current

$431.92

Performance

-12.07%

On Jan 28, 2026, HCA was evaluated by Sarah James, who gave a Overweight rating and target of 588. Investors saw limited payoff as shares fell short of the 588 target.

ACHC

Hold

Dec 03, 2025

Target

$22.00

Current

$27.58

Performance

87.75%

Sarah James rated ACHC as Neutral on Dec 03, 2025, setting a price target of 22. Despite the Hold call, shares climbed 87.75% to 27.58, revealing unexpected momentum.

CVS

Buy

Oct 30, 2025

Target

$95.00

Current

$80.98

Performance

5.59%

On Oct 30, 2025, CVS was given a Overweight rating by Sarah James, with a target price of 95. The stock rallied 5.59% after the rating, narrowing the gap to the target of 95 and validating the bullish stance.

THC

Buy

Oct 29, 2025

Target

$245.00

Current

$177.50

Performance

-15.13%

THC received a Overweight rating from Sarah James on Oct 29, 2025, aiming for 245. The rating hasn’t played out as hoped, with the stock trading 15.13% below expectations.

SGRY

Buy

Oct 07, 2025

Target

$36.00

Current

$14.35

Performance

-29.62%

On Oct 07, 2025, Sarah James published a Overweight outlook on SGRY, with a target of 36. Market action contradicted the Buy thesis, as shares slipped to 14.35.

CI

Buy

Aug 26, 2025

Target

$365.00

Current

$284.92

Performance

-5.13%

Sarah James on Aug 26, 2025 assigned CI a Overweight rating, with a price target of 365. The call has struggled to gain traction, with shares losing 5.13%.

UNH

Buy

Aug 26, 2025

Target

$440.00

Current

$366.77

Performance

22.08%

On Aug 26, 2025, Sarah James reaffirmed UNH with a Overweight rating, targeting 440. The recommendation was supported by strong follow-through as the stock rose from 366.77 to 366.77.

PGNY

Buy

Aug 08, 2025

Target

$28.00

Current

$18.38

Performance

-19.56%

PGNY was rated Overweight by Sarah James on Aug 08, 2025, with a price objective of 28. This case shows how bullish projections can fail, with the stock now below 18.38.

LFMD

Buy

Mar 11, 2025

Target

$15.00

Current

$4.55

Performance

-18.46%

On Mar 11, 2025, Sarah James initiated coverage on LFMD with a Overweight rating and target of 15. The Buy call has yet to be validated as shares remain 10.45 away from the target.

ELV

Buy

Jan 24, 2025

Target

$485.00

Current

$362.74

Performance

-9.53%

Sarah James issued a Overweight recommendation for ELV on Jan 24, 2025, price target set at 485. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

RCM

Hold

Oct 04, 2024

Target

$14.30

Current

$14.31

Performance

0.85%

On Oct 04, 2024, RCM was evaluated by Sarah James, who gave a Neutral rating and target of 14.3. Hold sentiment was validated by subdued trading with no breakout beyond 14.31.

TDOC

Buy

Aug 20, 2024

Target

$10.00

Current

$6.00

Performance

-16.67%

Sarah James rated TDOC as Overweight on Aug 20, 2024, setting a price target of 10. The stock has underperformed, dropping 16.67% despite the bullish target of 10.

AMED

Hold

Jul 25, 2024

Target

$101.00

Current

$100.99

Performance

3.31%

On Jul 25, 2024, AMED was given a Neutral rating by Sarah James, with a target price of 101. Market indecision, reflected in sideways trading near 100.99, supported the cautious call.

Frequency Asked Questions

Who is Sarah James?

Sarah James is an analyst from Cantor Fitzgerald specializing in the Healthcare sector.

What is Sarah James's success rate?

Sarah James currently has a success rate of +96.86%.

How many ratings has Sarah James issued?

Sarah James has issued 36 stock ratings so far.

What is the average return of Sarah James's calls?

Their stock ratings have generated an average return of +11.64%.

What is Sarah James's ranking?

Sarah James is ranked #1352 out of 4635 analysts.

What types of ratings does Sarah James give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Sarah James?

You can follow Sarah James by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Sarah James?

Their latest rating was a Hold on UHS issued on 2026-04-29.